Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.

Trial Profile

Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Advanced breast cancer; Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 17 Oct 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.
    • 14 Mar 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top